March 2, 2015 – Susanna Naggie, MD, and Andrew Muir, MD, MHS, each made presentations at this year’s meeting in Seattle.
The DCRI’s Susanna Naggie, MD, and Andrew Muir, MD, MHS, presented some of their latest research at the 22nd Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle.
Naggie (pictured) presented the results of a phase III trial evaluating a regimen of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus (HCV) in patients co-infected with HIV. The results of that study showed that 96 percent of HCV patients achieved a sustained virologic response 12 weeks (SVR12) after completing therapy. Patients who reach this benchmark are considered cured of HCV infection.
“This trial provides strong evidence that people who are co-infected with HIV can achieve very high rates of hepatitis C cure with a combination direct-acting antiviral regimen,” Naggie said. “These high cure rates were observed in most of the historically difficult-to-treat sub-populations, including those who failed previous treatment and those with cirrhosis. We are greatly encouraged by these findings.”
Muir’s presented the latest results of the UNITY-2 trial, which evaluated the safety and efficacy of an all-oral fixed dose combination of the drugs daclatasvir, asunaprevir, and beclabuvir with and without ribavirin in HCV patients with cirrhosis. That study found that the drug combination achieved high rates of SVR12 either with or without ribavirin and with minimal side effects.
Meredith Clement, MD, an infectious disease fellow at Duke, also presented research on statin guidelines and HIV-infected veterans.